| abstract |
The present invention relates to novel benzenesulfonanilide compounds of the Formulae (I) and (I') and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. (I) (I') F wherein R 1 is hydrogen or methyl; R 2 is hydrogen or methyl and is positioned vicinal to the radical R 1 ; R 3 hydrogen, C 1 -C 3 alkyl, halogen, C 1 -C 3 alkoxy, fluorinated C 1 -C 3 alkyl or fluorinated C 1 -C 3 alkoxy; R 4 is hydrogen, C 1 -C 4 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 cycloalkylmethyl or fluorinated C 1 -C 4 alkyl; R 5 is hydrogen, fluorine, chlorine, C 1 -C 4 alkyl, fluorinated C 1 -C 4 alkyl, C 1 -C 4 alkoxy or fluorinated C 1 -C 4 alkoxy; and R 6 is hydrogen, fluorine or chlorine. |